{"count": 6, "results": [{"_id": "36818016", "pmid": 36818016, "pmcid": "PMC9928947", "title": "The combined effect of metformin and mirabegron on diet-induced obesity", "journal": "MedComm (2020)", "authors": ["Zhao XY", "Liu Y", "Zhang X", "Zhao BC", "Burley G", "Yang ZC", "Luo Y", "Li AQ", "Zhang RX", "Liu ZY", "Shi YC", "Wang QP"], "date": "2023-02-14T00:00:00Z", "doi": "10.1002/mco2.207", "meta_date_publication": "2023 Apr", "meta_volume": "4", "meta_issue": "2", "meta_pages": "e207", "score": 50250.74, "text_hl": "The combined effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and @CHEMICAL_mirabegron @CHEMICAL_MESH:C520025 @@@mirabegron@@@ on diet-induced @DISEASE_Obesity @DISEASE_MESH:D009765 @@@obesity@@@", "citations": {"NLM": "Zhao XY, Liu Y, Zhang X, Zhao BC, Burley G, Yang ZC, Luo Y, Li AQ, Zhang RX, Liu ZY, Shi YC, Wang QP. The combined effect of metformin and mirabegron on diet-induced obesity MedComm (2020). 2023 Apr;4(2):e207. PMID: 36818016", "BibTeX": "@article{36818016, title={The combined effect of metformin and mirabegron on diet-induced obesity}, author={Zhao XY and Liu Y and Zhang X and Zhao BC and Burley G and Yang ZC and Luo Y and Li AQ and Zhang RX and Liu ZY and Shi YC and Wang QP}, journal={MedComm (2020)}, volume={4}, number={2}, pages={e207}}"}}, {"_id": "32591547", "pmid": 32591547, "pmcid": "PMC7320014", "title": "The importance of the AMPK gamma 1 subunit in metformin suppression of liver glucose production", "journal": "Sci Rep", "authors": ["An H", "Wang Y", "Qin C", "Li M", "Maheshwari A", "He L"], "date": "2020-06-26T00:00:00Z", "doi": "10.1038/s41598-020-67030-5", "meta_date_publication": "2020 Jun 26", "meta_volume": "10", "meta_issue": "1", "meta_pages": "10482", "score": 50248.973, "text_hl": "Furthermore, in @SPECIES_9606 @@@humans@@@ and animal models, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment leads to the @<m>DISEASE_Body_Weight</m> @DISEASE_MESH:D001835 @@@loss of body weight@@@, we found that the decrease in body @DISEASE_Weight_Gain @DISEASE_MESH:D015430 @@@weight gain@@@ in @SPECIES_10090 @@@mice@@@ treated with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ is not directly attributable to increased energy expenditure.", "citations": {"NLM": "An H, Wang Y, Qin C, Li M, Maheshwari A, He L. The importance of the AMPK gamma 1 subunit in metformin suppression of liver glucose production Sci Rep. 2020 Jun 26;10(1):10482. PMID: 32591547", "BibTeX": "@article{32591547, title={The importance of the AMPK gamma 1 subunit in metformin suppression of liver glucose production}, author={An H and Wang Y and Qin C and Li M and Maheshwari A and He L}, journal={Sci Rep}, volume={10}, number={1}, pages={10482}}"}}, {"_id": "24913417", "pmid": 24913417, "title": "Metformin in women with PCOS, pros.", "journal": "Endocrine", "authors": ["Pasquali R"], "date": "2015-03-01T00:00:00Z", "doi": "10.1007/s12020-014-0311-1", "meta_date_publication": "2015 Mar", "meta_volume": "48", "meta_issue": "2", "meta_pages": "422-6", "score": 50058.867, "text_hl": "The current Endocrine Society Guidelines recommend the use of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ during adolescence, particularly when @<m>DISEASE_Body_Weight</m> @DISEASE_MESH:D001835 @@@excess body weight@@@ is present. ", "citations": {"NLM": "Pasquali R. Metformin in women with PCOS, pros. Endocrine. 2015 Mar;48(2):422-6. PMID: 24913417", "BibTeX": "@article{24913417, title={Metformin in women with PCOS, pros.}, author={Pasquali R}, journal={Endocrine}, volume={48}, number={2}, pages={422-6}}"}}, {"_id": "15635851", "pmid": 15635851, "title": "[Short-term and long-term effect of metformin in type 1 diabetics].", "journal": "Vnitr Lek", "authors": ["Lacigová S", "Rusavý Z", "Kyselová P", "Jankovec Z", "Kárová R", "Cechurová D"], "date": "2001-02-01T00:00:00Z", "meta_date_publication": "2001 Feb", "meta_volume": "47", "meta_issue": "2", "meta_pages": "81-6", "score": 50049.8, "text_hl": "CONCLUSION: After adding @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ to the @GENE_INS @GENE_3630 @@@insulin@@@ regimen of @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetics@@@ after three months a statistically significant @<m>DISEASE_Body_Weight</m> @DISEASE_MESH:D001835 @@@drop of body weight@@@ and the daily @GENE_INS @GENE_3630 @@@insulin@@@ dose occurred. ", "citations": {"NLM": "Lacigová S, Rusavý Z, Kyselová P, Jankovec Z, Kárová R, Cechurová D. [Short-term and long-term effect of metformin in type 1 diabetics]. Vnitr Lek. 2001 Feb;47(2):81-6. PMID: 15635851", "BibTeX": "@article{15635851, title={[Short-term and long-term effect of metformin in type 1 diabetics].}, author={Lacigová S and Rusavý Z and Kyselová P and Jankovec Z and Kárová R and Cechurová D}, journal={Vnitr Lek}, volume={47}, number={2}, pages={81-6}}"}}, {"_id": "28276778", "pmid": 28276778, "title": "GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.", "journal": "Expert Rev Clin Pharmacol", "authors": ["Lamos EM", "Malek R", "Davis SN"], "date": "2017-04-01T00:00:00Z", "doi": "10.1080/17512433.2017.1292125", "meta_date_publication": "2017 Apr", "meta_volume": "10", "meta_issue": "4", "meta_pages": "401-408", "score": 50034.76, "text_hl": "Expert commentary: The available studies of @GENE_GLP1R @GENE_2740 @@@GLP-1@@@ RA therapy in the treatment of @<m>DISEASE_Body_Weight</m> @DISEASE_MESH:D001835 @@@excess body weight@@@ in @SPECIES_9606 @@@women@@@ with @DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@PCOS@@@ demonstrate that @CHEMICAL_Exenatide @CHEMICAL_MESH:D000077270 @@@exenatide@@@ and liraglutide are effective in @DISEASE_Weight_Loss @DISEASE_MESH:D015431 @@@weight@@@ reduction either as monotherapy or in combination with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. ", "citations": {"NLM": "Lamos EM, Malek R, Davis SN. GLP-1 receptor agonists in the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2017 Apr;10(4):401-408. PMID: 28276778", "BibTeX": "@article{28276778, title={GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.}, author={Lamos EM and Malek R and Davis SN}, journal={Expert Rev Clin Pharmacol}, volume={10}, number={4}, pages={401-408}}"}}, {"_id": "9235072", "pmid": 9235072, "title": "[Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].", "journal": "Invest Clin", "authors": ["Flórez H"], "date": "1997-03-01T00:00:00Z", "meta_date_publication": "1997 Mar", "meta_volume": "38", "meta_issue": "1", "meta_pages": "39-52", "score": 50021.54, "text_hl": "The drug therapy interventions include the @CHEMICAL_Biguanides @CHEMICAL_MESH:D001645 @@@biguanide@@@ @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and the @CHEMICAL_2_4_thiazolidinedione @CHEMICAL_MESH:C089946 @@@thiazolidinedione@@@ troglizatone. ", "citations": {"NLM": "Flórez H. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations]. Invest Clin. 1997 Mar;38(1):39-52. PMID: 9235072", "BibTeX": "@article{9235072, title={[Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].}, author={Flórez H}, journal={Invest Clin}, volume={38}, number={1}, pages={39-52}}"}}]}